No committee data
Expert AnalysisPro
/ 100 Political Alpha
Upgrade to see committee overlap, performance context, and full expert analysis.
Buy price
Return since trade
Follow $10K gain
Expert analysis is Pro-only
UpgradeLive
Track congressional trades for BRYBRY congressional trades
2 matched disclosures
Tracked disclosures
2
Lawmakers
1
Buy / sell
0 / 2
Avg post-trade move
N/A
Latest filing 2025-10-06
BRY congressional trades snapshot
This page summarizes public STOCK Act disclosures involving BRY. It is useful for seeing which lawmakers reported BRY transactions, how many filings are visible, the buy/sell mix, and whether the newest public filing describes a recent or delayed trade.
Last updated
Oct 6, 2025
Data source
Public House and Senate STOCK Act disclosures normalized by Congressional Trader.
Key caveat
Filing date can trail transaction date. This page is for research and monitoring, not investment advice.
What the BRY congressional trade page shows
Congressional Trader tracks 2 public STOCK Act disclosures for BRYacross 1 lawmakers. This page separates purchases from sales, shows filing delays, and links each disclosure back to the individual politician profile when available.
The most recent BRY filing shown here was filed on Oct 6, 2025 by Debbie Wasserman Schultz as a sale. Related lawmakers include Debbie Wasserman Schultz.
Top lawmakers for BRY
Pro performance summary
Unlock 30/90-day post-trade summaries, committee overlap, and CSV-oriented research views for high-intent ticker research.
Compare Pro plansNo committee data
Expert AnalysisPro
/ 100 Political Alpha
Upgrade to see committee overlap, performance context, and full expert analysis.
Buy price
Return since trade
Follow $10K gain
Expert analysis is Pro-only
UpgradeFAQ
Which lawmakers traded BRY?
Recent BRY disclosures include Debbie Wasserman Schultz.
What is the buy/sell mix for BRY?
The visible sample currently shows 0 purchases and 2 sales or partial sales.
Should I trade based on BRY disclosures?
No. This page summarizes public filings for research and monitoring. It is not investment advice.